VEA
INO icon

Virtus ETF Advisers’s Inovio Pharmaceuticals INO Stock Holding History

Virtus ETF Advisers’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,509
Closed -$44.4K – 459
2023
Q1 		$44.4K Sell
4,509
-1,733
-28% -$29.5K 0.02% 432
2022
Q4 		$117K Buy
6,242
+197
+3% +$4.46K 0.06% 428
2022
Q3 		$125K Buy
6,045
+44
+0.7% +$1.13K 0.05% 386
2022
Q2 		$125K Buy
6,001
+3,814
+174% +$107K 0.05% 372
2022
Q1 		$94K Sell
2,187
-129
-6% -$5.81K 0.04% 313
2021
Q4 		$139K Buy
2,316
+328
+16% +$26.3K 0.05% 361
2021
Q3 		$171K Sell
1,988
-104
-5% -$10.4K 0.08% 307
2021
Q2 		$233K Sell
2,092
-312
-13% -$30K 0.1% 236
2021
Q1 		$268K Buy
2,404
+42
+2% +$5.52K 0.11% 269
2020
Q4 		$251K Buy
+2,362
New +$314K 0.1% 312
2019
Q2 		– Sell
-4,412
Closed -$197K – 440
2019
Q1 		$197K Sell
4,412
-621
-12% -$31.3K 0.42% 90
2018
Q4 		$242K Sell
5,033
-3,634
-42% -$221K 0.04% 164
2018
Q3 		$578K Sell
8,667
-6,197
-42% -$345K 0.06% 107
2018
Q2 		$699K Buy
14,864
+299
+2% +$16.5K 0.62% 102
2018
Q1 		$823K Buy
14,565
+7,827
+116% +$424K 0.71% 68
2017
Q4 		$334K Buy
6,738
+3,302
+96% +$205K 0.42% 110
2017
Q3 		$261K Buy
3,436
+314
+10% +$23.4K 0.04% 136
2017
Q2 		$294K Sell
3,122
-239
-7% -$20.4K 0.04% 128
2017
Q1 		$267K Buy
3,361
+322
+11% +$25.7K 0.05% 155
2016
Q4 		$253K Buy
3,039
+1,034
+52% +$93.5K 0.08% 138
2016
Q3 		$224K Hold
2,005
– – 0.11% 131
2016
Q2 		$222K Sell
2,005
-1,369
-41% -$166K 0.16% 123
2016
Q1 		$353K Buy
+3,374
New +$260K 0.49% 55

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Virtus ETF Advisers's INO Position: Q2 2023 in Review

Virtus ETF Advisers sold out of Inovio Pharmaceuticals (INO) in Q2 2023, closing a stake of 4,509 shares — an estimated $44.4K sold.

Virtus ETF Advisers first reported a position in INO in Q1 2016 and held it in 23 quarters. The position peaked at $823K in Q1 2018. 133 funds tracked by Wall St. Rank hold INO as of Q2 2023.

  • Virtus ETF Advisers reported no remaining Inovio Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 4,509 Inovio Pharmaceuticals shares in Q2 2023, an estimated $44.4K.
  • Virtus ETF Advisers first reported a position in Inovio Pharmaceuticals in Q1 2016 and held it in 23 quarters.
  • Virtus ETF Advisers's Inovio Pharmaceuticals position peaked at $823K in Q1 2018.
  • 133 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2023.

Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.